In another study, anti-CSF-1R significantly improved the anti-tumor effect of combined IT, consisting of anti-CTLA and anti-PD-L1, in pancreatic carcinoma models [23]. The gene discussed is CSF1R; the disease is exocrine pancreatic carcinoma.